Matt Gethers/Articles to Read/Social 2
Social 2
Science on trial (Eathquake prosecutions)
Reply to Murray and Schloss: Designer genes?
Bilski v. Kappos: the US Supreme Court broadens patent subject-matter eligibility
DNA patents and diagnostics: not a pretty picture
Synthetic Biology: Now that We're Creators, What Should We Create?
Why you need a lawyer: What's involved in formally starting a biotech company?
Five "C's" of successful startups
History of science is good for you
Patent protection for DNA sequences – to be or not to be?
US Supreme Court returns patent-eligibility test to fundamental principles
Synthetic biology and the ethics of knowledge.
Safe and effective synthetic biology
Building a strategy for maximizing intellectual property value
A blocking patent can kill your business before it's off the ground.
A shadow falls over gene patents in the United States and Europe
Grant management skills are critical for young scientists
Getting it right the first time (Business development)
Streamlining your business for success
Science in the service of citizens and consumers
Biotech and gender issues in the developing world
Should moral objections to synthetic biology affect public policy?
From synthetic biology to biohacking: are we prepared?
US government report recommends a "principle of regulatory parsimony" for synthetic biology.
How the EU can fund your company
The ‘real world’ utility of miRNA patents: lessons learned from expressed sequence tags
Towards a medical grade human genome sequence
Judging the Archon Genomics X PRIZE for whole human genome sequencing
NIH Director’s Early Independence Award (EIA)
Amorous for Amyris: 4 months post-IPO, bulls are running – what do we know?
When IP lawyers pay a visit to the lab
Unsettled expectations: how recent patent decisions affect biotech
Four steps to finding the right people
Personal genomics to the people
Mixed messages from Washington
Intellectual property rights in publicly funded biobanks: much ado about nothing?
